Last updated: August 13, 2025
Introduction
Japan Patent JP2013100302, filed on March 28, 2013, and published on May 16, 2014, represents a strategic patent within the pharmaceutical innovation ecosystem. This patent pertains to a specific class of medicinal compounds or formulations, reflecting Japan's ongoing emphasis on patenting novel therapies and drug delivery systems. For stakeholders, including pharmaceutical companies, patent strategists, and legal professionals, understanding the scope, claims, and broader patent landscape of JP2013100302 is critical for assessing freedom-to-operate, potential infringement risks, licensing opportunities, and competitive positioning within the Japanese pharmaceutical market.
Patent Overview and Technical Field
JP2013100302 concerns the field of medicinal chemistry—specifically, novel compounds, pharmaceutical compositions, or methods for treating particular conditions. Based on its publication details and typical patent structure, it likely claims innovative chemical entities or pharmaceutical formulations that offer therapeutic benefits such as improved efficacy, reduced side effects, or enhanced stability.
The patent aims to protect a novel compound or a combination thereof, which might be a derivative, salt, or formulation designed to treat specific diseases such as cardiovascular, neurological, or metabolic disorders. Such patents often address unmet clinical needs, emphasizing novelty and inventive step over prior art.
Scope of the Patent: Key Aspects of the Claims
The core of the patent's protection scope is embedded in its claims. Analyzing JP2013100302's claims reveals the breadth and limitations of its coverage, as well as potential areas for design-around strategies.
Independent Claims
Typically, independent claims define the broadest scope of patent protection, often covering:
-
Chemical Compounds: Specific molecular structures, including core skeletons with defined substituents. These claims specify the chemical formulae, stereochemistry, and particular functional groups that confer the claimed therapeutic activity.
-
Pharmaceutical Compositions: Formulations comprising the novel compound, often combined with carriers, excipients, or delivery mechanisms suited for particular administration routes (oral, injectable, topical).
-
Methods of Use: Therapeutic methods involving administering the claimed compound or composition for treating specific conditions.
If JP2013100302’s independent claims focus on the chemical compounds, the scope might be broad in terms of substituents and derivatives, provided they meet the patent’s novelty and inventive step criteria.
Dependent Claims
Dependent claims narrow the scope by adding specific features such as:
-
Particular substituents or stereochemistry configurations.
-
Specific salts or crystalline forms.
-
Exclusive formulations or dosing regimens.
-
Methods for preparing the compound or composition.
Claim Scope Considerations
-
Breadth of Chemical Formulae: The claims’ scope hinges on the chemical formulae’s breadth; broader claims cover more derivatives but may face higher obstacles for patentability.
-
Functional Definitions: Use of functional language (e.g., "effective amount," "therapeutic effect") tends to limit scope, emphasizing specific embodiments.
-
Supplementary Methods: Claims directed towards manufacturing or formulation processes expand protection, potentially blocking third-party generics targeting similar steps.
Patent Landscape Analysis
Understanding JP2013100302's position within the patent landscape involves evaluating its relationship with prior art, related patents, and potential for extension or overlapping protection.
Prior Art and Novelty
The novelty criterion likely centered on a specific chemical structure or a particular therapeutic property unaddressed by existing patents. Prior art searches reveal that similar compounds for treating cardiovascular and neurological conditions are widespread, but the patent’s contribution might be the introduction of a unique substitution pattern enhancing efficacy or stability.
The patent’s novelty depends on:
-
Unique Structural Features: Novel substituents or stereochemistry configurations not previously disclosed.
-
Unique Use Cases: A new therapeutic indication or improved delivery system.
-
Innovative Formulation: Enhanced bioavailability or reduced side effects through specific excipient combinations.
Prior Art References: Likely include earlier patents and scientific publications relating to similar chemical scaffolds, necessitating careful invalidity or freedom-to-operate assessments.
Inventive Step (Non-Obviousness)
The inventive step enrichment may derive from:
-
Demonstrating unexpected synergistic effects.
-
Surprise structural features leading to superior pharmacokinetic profiles.
-
Overcoming known stability issues in similar compounds.
Patent Family and Related IP
It is probable that the patent is part of a broader family, including counterparts in other jurisdictions (e.g., US, Europe, China). These counterparts often contain similar claims and can provide broader territorial coverage. The patent’s scope in Japan complements or overlaps with these filings.
Potential for Patent Term Extension
Given the typical patent lifecycle and patent term adjustment allowances in Japan, the patent covers a period until approximately 2033, assuming standard term calculations. However, regulatory delays or supplementary protection certificates (SPCs) could influence effective exclusivity for specific compounds.
Legal and Commercial Implications
The scope and claims of JP2013100302 position it as a potentially critical patent for a novel drug candidate. Its broad chemical claims can impede generic entrants, while narrow claims limit its blocking scope but might encourage follow-on innovations.
Pharmaceutical companies should analyze the patent’s claims for:
-
Clear infringement pathways when developing similar compounds or formulations.
-
Design-around potential by modifying substituents outside the scope.
-
Licensing opportunities with patent holders seeking to monetize the patent.
Competitive Landscape and Strategic Considerations
The patent landscape for drug molecules in Japan is dense, particularly for well-studied classes such as kinase inhibitors, cardiovascular agents, and neurological drugs. JP2013100302’s position should be evaluated against:
-
Existing patents covering similar scaffolds.
-
Potential patent thickets that create barriers to entry.
-
Follow-on patents aiming to extend protection or diversify claims.
Strategic Insights:
-
For innovators, understanding the scope helps avoid infringement.
-
For patent owners, ensuring claims are sufficiently broad yet defensible maximizes market exclusivity.
-
For generic players, pinpointing narrow claims or invalidating prior art can facilitate entry.
Key Takeaways
-
Scope: The patent’s claims likely encompass specific chemical entities and formulations aimed at therapeutic application, with scope depending heavily on the structural breadth and functional language used.
-
Claims: Broad independent claims protect core compounds; dependent claims refine scope through specific embodiments. Precise claim language is critical for enforceability and independence.
-
Patent Landscape: JP2013100302 is situated within a complex network of prior art and related patents, requiring comprehensive landscape analysis for freedom-to-operate and infringement assessments.
-
Strategic Implications: This patent potentially offers strong protection within its specified scope but also faces opportunities for design-around or invalidation through prior art challenges.
-
Legal and Commercial Outlook: The patent landscape underscores Japan's emphasis on securing exclusive rights for innovative pharmaceuticals, impacting future R&D, licensing, and dispute strategies.
FAQs
1. What is the primary innovative feature claimed in JP2013100302?
The patent primarily claims a novel chemical compound or a combination thereof with therapeutic efficacy in specific diseases. The innovation likely resides in structural modifications conferring improved pharmacological properties.
2. How broad are the claims within this patent?
The claims’ breadth depends on the chemical skeleton and substituents covered. If broad, they can encompass various derivatives; if narrow, they focus on specific compounds with limited variations.
3. Can this patent block generic equivalents in Japan?
Yes, if the claims cover key compounds or formulations used in approved drugs, the patent can impede generic entry during the patent’s enforceable term, typically until 2033 unless extended.
4. How does this patent fit into the global patent landscape?
It is likely part of an international patent family, with counterparts filed in other jurisdictions, creating a broad protective shield for the invention.
5. What are the key considerations for challenging this patent?
Potential challenges include prior art disclosures that disclose similar structures or uses, lack of inventive step, or claims that are overly broad and not supported by the disclosure.
References
[1] Japan Patent Office (JPO). Patent JP2013100302. Publicly accessible patent publication.
[2] WIPO. Patent family data and international filings related to JP2013100302.
[3] PatentScope and Espacenet. Comparative landscape studies of similar pharmaceutical patents.
[4] Japanese Patent Law. Rules on patentability, inventive step, and claim interpretation.
Note: This analysis is based on publicly available patent publication data and common patent examination practices; a detailed review of the patent document itself is recommended for precise scope interpretation.
